Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment

T cell interaction in the tumor microenvironment is a key component of immuno‐oncology therapy. Glucocorticoid‐induced tumor necrosis factor receptor (TNFR)‐related protein (GITR) is expressed on immune cells including regulatory T cells (Tregs) and effector T cells (Teffs). Preclinical data suggest that agonism of GITR in combination with Fc‐γ receptor‐mediated depletion of Tregs results in increased intratumoral Teff:Treg ratio and tumor shrinkage. A novel quantitative systems pharmacology (QSP) model was developed for the murine anti‐GITR agonist antibody, DTA‐1.mIgG2a, to describe the kinetics of intratumoral Tregs and Teffs in Colon26 and A20 syngeneic mouse tumor models. It adequately captured the time profiles of intratumoral Treg and Teff and serum DTA‐1.mIgG2a and soluble GITR concentrations in both mouse models, and described the response differences between the two models. The QSP model provides a quantitative understanding of the trade‐off between maximizing Treg depletion versus Teff agonism, and offers insights to optimize drug design and dose regimen.

[1]  J. Mataraza,et al.  Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose , 2022, Clinical and translational science.

[2]  Rob J. de Boer,et al.  Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity , 2021, Nature Communications.

[3]  Angad P. Singh,et al.  First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas , 2021, Journal for ImmunoTherapy of Cancer.

[4]  N. Rizvi,et al.  Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors , 2020, Clinical Cancer Research.

[5]  E. Rasmussen,et al.  Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors , 2018, Journal of Immunotherapy for Cancer.

[6]  J. Welsh,et al.  Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects , 2018, Front. Immunol..

[7]  K Gadkar,et al.  A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.

[8]  Ramon Arens,et al.  In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity , 2016, Immunity.

[9]  J. Wolchok,et al.  GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability , 2013, Cancer Immunology Research.

[10]  P. Vicini,et al.  A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics , 2013, The AAPS Journal.

[11]  A. Ashkenazi,et al.  Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies , 2013, The Journal of experimental medicine.

[12]  G. Dranoff,et al.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.

[13]  Yijun Carrier,et al.  Enhanced GITR/GITRL interactions augment IL‐27 expression and induce IL‐10‐producing Tr‐1 like cells , 2012, European journal of immunology.

[14]  C. Riccardi,et al.  CD8+ T Cells: GITR Matters , 2012, TheScientificWorldJournal.

[15]  J. Wolchok,et al.  Modulation of GITR for cancer immunotherapy. , 2012, Current opinion in immunology.

[16]  C. Riccardi,et al.  Pharmacological modulation of GITRL/GITR system: therapeutic perspectives , 2012, British journal of pharmacology.

[17]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[18]  Taeg S. Kim,et al.  The Cell Cycle Time of CD8+ T Cells Responding In Vivo Is Controlled by the Type of Antigenic Stimulus , 2010, PloS one.

[19]  Y. Setiady,et al.  In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes , 2010, European journal of immunology.

[20]  Ugo Del Monte,et al.  Does the cell number 10(9) still really fit one gram of tumor tissue , 2009 .

[21]  C. Riccardi,et al.  GITR: a modulator of immune response and inflammation. , 2009, Advances in experimental medicine and biology.

[22]  P. Zhou,et al.  Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors , 2007, The Journal of Immunology.

[23]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[24]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[25]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[26]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.